ACHV Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Achieve Life Sciences's net margin of 12.11%. Achieve Life Sciences's return on equity of -- beat Electromed's return on equity of 15.91%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 633.95%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 64.23%. Given that Achieve Life Sciences has higher upside potential than Electromed, analysts believe Achieve Life Sciences is more attractive than Electromed.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Achieve Life Sciences's net income of -$12.4M is lower than Electromed's net income of $2M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Electromed's PE ratio is 30.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 3.38x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -- compared to Achieve Life Sciences's net margin of -63.22%. Achieve Life Sciences's return on equity of -- beat Nuwellis's return on equity of -800.59%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 633.95%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1295.12%. Given that Nuwellis has higher upside potential than Achieve Life Sciences, analysts believe Nuwellis is more attractive than Achieve Life Sciences.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.510, suggesting its less volatile than the S&P 500 by 49.013%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Nuwellis quarterly revenues of $2.3M. Achieve Life Sciences's net income of -$12.4M is lower than Nuwellis's net income of -$1.5M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 0.17x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Achieve Life Sciences's net margin of -18.58%. Achieve Life Sciences's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 633.95%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Achieve Life Sciences has higher upside potential than Retractable Technologies, analysts believe Achieve Life Sciences is more attractive than Retractable Technologies.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Achieve Life Sciences's net income of -$12.4M is lower than Retractable Technologies's net income of -$1.9M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Achieve Life Sciences's net margin of -118.53%. Achieve Life Sciences's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 633.95%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 171.08%. Given that Achieve Life Sciences has higher upside potential than Stereotaxis, analysts believe Achieve Life Sciences is more attractive than Stereotaxis.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Achieve Life Sciences's net income of -$12.4M is lower than Stereotaxis's net income of -$7.5M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 5.25x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.